References
- McCamish M, Woollett G. Worldwide experience with biosimilar development. mAbs. 2011;3(2):209–217.
- Blackstone EA, Joseph PF. The economics of biosimilars. Am Health Drug Benefits. 2013 Sep;6(8):469–478.
- Food and Drug Administration. Biosimilar and interchangeable products. 2018 [cited 2018 Jan 28]. Available from: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm580419.htm-biosimilar
- Biologics Price Competition and Innovation Act of 2009. [Cited 2017 Aug 13]. Available from: https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/ucm216146.pdf
- Morton FMS, Stern AD, Stern S. The impact of the entry of biosimilars: evidence from Europe. Harvard Business School Working Paper, No. 16-141. 2017; Available from: https://www.hbs.edu/faculty/Pages/item.aspx?num=51309
- Shepherd JM Biologic drugs, biosimilars, and barriers to entry. [cited 2018 Jan 28]. Available from: https://pdfs.semanticscholar.org/0923/396df2e920c9d7c74dca817d42d4b8b0df7b.pdf
- Wong AY, Rumore MM, Chan AW. Biosimilars in the United States: emerging issues in litigation. BioDrugs. 2017 Jun;31(3):189–205.
- Reiffen D, Ward MR Generic drug industry dynamics. Rev Econ Stat. 2005;87(1):37–49.
- Christl LA, Woodcock J, Kozlowski S. Biosimilars: the US regulatory framework. Annu Rev Med. 2017 Jan 14; 681:243–254.
- Acemoglu D, Linn J. Market size in innovation: theory and evidence from the pharmaceutical industry. Q J Econ. 2004;119(3):1049–1090.
- Ramachandra S. Lessons for the United States: biosimilar market development worldwide. 2017 [cited 2018 Jan 28]. Available from: https://www.ftc.gov/system/files/documents/public_events/Follow-On Biologics Workshop%3A Impact of Recent Legislative and Regulatory Naming Proposals on Competition/ramachandra.pdf
- Stern AD Essays in the economics of health care and the regulation of medical technology. 2014 [cited 2018 Jan 28]. Available from: https://dash.harvard.edu/handle/1/12274288
- Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol. 2008 Mar;19(3):411–419.
- Ebbers HC. Biosimilars: in support of extrapolation of indications. J Crohns Colitis. 2014 May;8(5):431–435.
- Food and Drug Administration. Considerations in demonstrating the interchangeability with a reference product: guidance for industry (draft for commentary). In: editor. U.S. Department of Health and Human Services. Washington D.C.: Food and Drug Administration. 2017.
- Singh SC, Bagnato KM. The economic implications of biosimilars. Am J Manag Care. 2015 Dec;21(16 Suppl):s331–40.
- Zelenetz AD, Ahmed I, Braud EL, et al. NCCN biosimilars white paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw. 2011 Sep;9(Suppl 4):S1–22.
- Federal Trade Commission. ‘In response to a request for comments on its guidance for industry on the “Nonproprietary Naming of Biological Products; Draft Guidance for Industry; Availability”’. [Docket No. FDA-2013-D-1543]2. 80 Fed. Reg. 52296. Washington, DC: Federal Trade Commission. 2015
- IMS Health. The impact of biosimilar competition. 2016 [cited 2018 Jan 28]. Available from: https://ec.europa.eu/docsroom/documents/17325/attachments/1/translations/en/renditions/native
- Grabowski H, Guha R, Salgado M. Biosimilar competition: lessons from Europe. Nat Rev Drug Discov. 2014 Feb;13(2):99–100.
- Medicare Modernization Act, Section 303(c) Title XVII Section 1847a.
- Cohen JP, Felix AE, Riggs K Barriers to market uptake of biosimilars in the US: generics and biosimilars initiative. GaBIJ. 2014;3(3):108–115.
- Payer perspectives on biosimilars. 2017 [cited 2018 Jan 28]. Available from: http://www.xcenda.com/Insights-Library/Payer-Perspectives/Payer-Perspectives-on-Biosimilars/
- Blackwell K, Semiglazov V, Krasnozhon D, et al. Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy. Ann Oncol. 2015 Sep;26(9):1948–1953.
- Vanderpuye-Orgle J, Sexton Ward A, Huber C, et al. Estimating the social value of G-CSF therapies in the United States. Am J Manag Care. 2016 Oct 1;22(10):e343–e9.
- SEER stat fact sheets: cancer of any site. National Cancer Institute website. 2014 [cited 2014 Nov 5]. Available from: http://seer.cancer.gov/statfacts/html/all.html
- Naeim A, Henk HJ, Becker L, et al. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF). BMC Cancer. 2013 Jan 13;1:11.
- Mulcahy Andrew W, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. 2017 [cited 2018 Jan 28]. Available from: https://www.rand.org/pubs/perspectives/PE264.html
- Sandoz. Personal communication. [Cited 2017 Apr 22].
- Medicare Payment Advisory Commission. Report to congress: Medicare and the health care delivery system. 2015 [cited 2018 Jan 28]. Available from: http://www.medpac.gov/docs/default-source/reports/june-2015-report-to-the-congress-medicare-and-the-health-care-delivery-system.pdf?sfvrsn=0
- Generics and Biosimilars Initiative (GABI) Online. Use of biosimilars in Europe differs across countries. 2014 [cited 2018 Jan 28]. Available from: http://www.gabionline.net/Reports/Use-of-biosimilars-in-Europe-differs-across-countries
- Andrew W, Mulcahy ZP, Mattke S. The cost savings potential of biosimilar drugs in the United States. 2016 [cited 2018 Jan 28]. Available from: https://www.rand.org/pubs/perspectives/PE264.html
- Kopenski F, Holcomb K. Understanding biosimilars and projecting the cost savings to employers-update. 2015. [Cited 2018 Jan 28].
- Schiestl M, Krendyukov A. The ESMO position paper on biosimilars in oncology: enhancing the provision of accurate education and information. ESMO Open. 2017;2(3):e000245.
- Lyman GH, Balaban E, Diaz M, et al. American Society of Clinical Oncology statement: biosimilars in oncology. J Clin Oncol. 2018 Apr 20;36(12):1260–1265.
- The World Bank. 2016 Population growth (annual%) data. [cited 2016 Dec 15]. Available from: http://data.worldbank.org/indicator/SP.POP.GROW?end=2015&locations=US&start=2015&view=bar
- Smoyer KE, Johnson BH, Jones CA, et al. Uptake of Tbo-filgrastim in the outpatient setting among commercially insured and Medicare supplemental populations in the United States. Washington DC: ISPOR; 2017.